Identification of enzymes responsible for nitrazepam metabolism and toxicity in human.

作者: Keigo Konishi , Tatsuki Fukami , Saki Gotoh , Miki Nakajima

DOI: 10.1016/J.BCP.2017.06.114

关键词: Arylacetamide deacetylaseEnzymeHydroxylationAldehyde oxidase 1ReductaseChemistryMicrosomeMetaboliteCYP3A4Biochemistry

摘要: Nitrazepam (NZP) is a hypnotic agent that rarely causes liver injuries in humans and teratogenicity rodents. In humans, NZP primarily metabolized to 7-aminonitrazepam (ANZP) by reduction subsequently 7-acetylamino nitrazepam (AANZP) acetylation. ANZP can be regenerated from AANZP hydrolysis rodents, but it still unclear whether this reaction occurs humans. may associated with teratogenicity, while known drug-induced caused reactive metabolite(s). study, we attempted identify the enzymes responsible for metabolism obtain basic understanding of process metabolite toxicities. We found reductase activity human cytosol (HLC) was higher than microsomes (HLM). purified enzyme(s) HLC aldehyde oxidase 1 (AOX1). The role AOX1 confirmed an observed increase upon addition N1-methylnicotinamide, electron donor AOX1, as well inhibition presence inhibitors. acetylated form N-acetyltransferase (NAT) 2. An experiment using recombinant esterases study HLM revealed hydrolyzed arylacetamide deacetylase (AADAC) liver. N-Hydroxylamino NZP, which suspected metabolite, detected conjugate N-acetyl-l-cysteine through hydroxylation reactions. latter reaction, readily formed CYP3A4 among various P450 isoforms tested. sum, NAT2, AADAC, are determinants pharmacokinetics they confer interindividual variability sensitivity side effects.

参考文章(54)
Tatsuki Fukami, Motoki Kariya, Takaya Kurokawa, Azumi Iida, Miki Nakajima, Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases. European Journal of Pharmaceutical Sciences. ,vol. 78, pp. 47- 53 ,(2015) , 10.1016/J.EJPS.2015.07.006
Am Holbrook, R Crowther, A Lotter, Yohannes Endeshaw, The role of benzodiazepines in the treatment of insomnia Journal of the American Geriatrics Society. ,vol. 49, pp. 824- 826 ,(2001) , 10.1046/J.1532-5415.2001.49161.X
D. J. Newton, R. W. Wang, A. Y. H. Lu, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition. ,vol. 23, pp. 154- 158 ,(1995)
Kadlubar Ff, Beland Fa, Guengerich Fp, Hammons Gj, Weis Cc, Metabolic Oxidation of Carcinogenic Arylamines by Rat, Dog, and Human Hepatic Microsomes and by Purified Flavin-containing and Cytochrome P-450 Monooxygenases Cancer Research. ,vol. 45, pp. 3578- 3585 ,(1985)
L C Quattrochi, J O Miners, R H Tukey, M E McManus, H V Gelboin, D J Birkett, M E Veronese, W Tassaneeyakul, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics. ,vol. 265, pp. 401- 407 ,(1993)
Nasir Zahid, Iain Gardner, Jack P. Uetrecht, Duncan MacCrimmon, A Comparison of the Oxidation of Clozapine and Olanzapine to Reactive Metabolites and the Toxicity of these Metabolites to Human Leukocytes Molecular Pharmacology. ,vol. 53, pp. 991- 998 ,(1998)
Earl S. Ford, Timothy J. Cunningham, Wayne H. Giles, Janet B. Croft, Trends in insomnia and excessive daytime sleepiness among US adults from 2002 to 2012 Sleep Medicine. ,vol. 16, pp. 372- 378 ,(2015) , 10.1016/J.SLEEP.2014.12.008
Dmitri R. Davydov, Nadezhda Y. Davydova, Elena V. Sineva, Irina Kufareva, James R. Halpert, Pivotal role of P450-P450 interactions in CYP3A4 allostery: the case of α-naphthoflavone. Biochemical Journal. ,vol. 453, pp. 219- 230 ,(2013) , 10.1042/BJ20130398